CTOs on the Move

Inform Genomics

www.informgenomics.com

 
Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data ...
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Carl Moor
Chief Technology Officer Profile

Similar Companies

TriNetX

TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. TriNetX combines EMR data such as demographics, diagnoses, procedures, medications, labs, genomics, and deep oncology data with data derived from clinical documentation including discharge summaries, radiology reports, pathology reports, and others, to deliver the industry`s most comprehensive data set for protocol design, feasibility, site selection and patient identification.

Oxyband Technologies

Oxyband Technologies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SkinMedica

SkinMedica, Inc. is a specialty pharmaceutical company focused on developing, acquiring and commercializing products that treat dermatologic conditions and diseases, and improve the appearance of skin. Through the Company's own sales force, it markets

Access BIO

Access BIO is a Boyce, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases